Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 7/20 | 0.42 |
| ▸ | CDK4 | P11802 | 3/20 | 0.42 |
| ▸ | CCND1 | P24385 | 3/20 | 0.42 |
| ▸ | STAT6 | P42226 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643117 | 0.88 | CCND3 (0.56) | ALKAXLCDK4CCND1SYK | |
| SCHEMBL1115334 | 0.88 | ALK (0.50) | ALKCDK4CCND1CDK2CDK1 | |
| SCHEMBL1644121 | 0.87 | CDK4 (0.37) | ALKAXLCDK4CCND1STAT6 | |
| SCHEMBL1115407 | 0.86 | CDK4 (0.47) | CDK4CCND1STAT6CDK2CDK1 | |
| SCHEMBL1643626 | 0.85 | WEE1 (0.47) | CDK4CCND1STAT6CDK2CDK1 | |
| SCHEMBL2569620 | 0.84 | ALK (0.45) | ALKAXLCDK4CCND1STAT6 | |
| SCHEMBL1643760 | 0.83 | WEE1 (0.47) | CDK4CCND1STAT6CDK2CDK1 | |
| SCHEMBL1115182 | 0.83 | CDK4 (0.48) | ALKAXLCDK4CCND1STAT6 | |
| SCHEMBL1115314 | 0.82 | ALK (0.41) | ALKCDK4CCND1STAT6SYK | |
| SCHEMBL1115132 | 0.80 | STAT6 (0.44) | ALKCDK4CCND1STAT6SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | CDK4, CDK3, CDK6 | ALK 2638/4885AXL 478/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.